>Mercado de vacinas da América do Norte, por composição (vacinas combinadas, monovacinas), tipo (subunidade, recombinante, polissacárido e vacinas conjugadas, vacinas vivas atenuadas, vacinas inativadas, vacinas toxóides, vacinas de ADN), tipo (vacina de rotina, vacina recomendada, vacina necessária) ), Idade de administração (vacina pediátrica, vacina para adultos), doenças (doença pneumocócica, sarampo, papeira e varicela, DPT, hepatite, gripe, febre tifóide, meningocócica, raiva, encefalite japonesa, febre amarela, outras ), via de administração (injetável , Oral, Nasal), Utilizador Final (Hospitais Comunitários, Hospitais, Centros Especializados, Clínicas, Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online), País (EUA, Canadá, México) Tendências e Previsão da Indústria para 2028
Análise e insights de mercado: Mercado de vacinas na América do Norte
Espera-se que o mercado de vacinas ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 6,6% no período de previsão de 2021 a 2028 e deverá atingir os 27.802,69 milhões de dólares até 2028. A elevada prevalência de condições crónicas, como a gripe e as doenças infeciosas bacterianas, e a presença de produtos em pipeline são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
As vacinas são o produto que tem a capacidade de reduzir o risco de contrair uma doença, trabalhando com o próprio sistema imunitário do organismo, de forma a aumentar a proteção contra os agentes patogénicos mortais. Foram descobertos vários tipos de vacinas para doenças potencialmente fatais que previnem cerca de 2 a 3 milhões de mortes todos os anos causadas por doenças como o tétano, a difteria, a tosse convulsa, o sarampo e a gripe, entre outras.
O lançamento de novas e inovadoras vacinas conquista a crença dos doentes e proporciona ao mercado um novo futuro que poderá ter um efeito positivo no crescimento do mercado das vacinas. Além disso, o lançamento de novas vacinas mostra também que os intervenientes no mercado estão constantemente empenhados no crescimento do mercado das vacinas. Isto significa, portanto, que a introdução de produtos inovadores atua como motor para o crescimento do mercado das vacinas. Os processos de regulação e formação de documentos das empresas fabricantes nos diferentes países podem dificultar o crescimento do mercado das vacinas. Os players do mercado que operam no mercado das vacinas estão a adotar diversas iniciativas estratégicas que deverão proporcionar oportunidades para os seus negócios em diversas dimensões e liderar o crescimento do mercado das vacinas. O receio dos doentes em relação às injeções e picadas de agulhas atua como desafio para o crescimento do mercado das vacinas.
O relatório de mercado de vacinas fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos , decisões estratégicas, lançamentos de produtos, geografia expansões e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito do mercado de vacinas da América do Norte e dimensão do mercado
O mercado das vacinas é segmentado com base na composição, tipo, tipo, idade de administração, doenças, via de administração, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base na composição, o mercado das vacinas está segmentado em vacinas combinadas, monovacinas. Em 2021, o segmento das vacinas combinadas está a dominar o mercado porque as vacinas combinadas são eficazes contra múltiplas doenças através da administração de uma única dose.
- Com base no tipo, o mercado das vacinas está segmentado em vacinas subunitárias, recombinantes, polissacáridas e conjugadas, vacinas vivas atenuadas, vacinas inativadas, vacinas toxóides e vacinas de ADN. Em 2021, o segmento das vacinas de subunidades, recombinantes, polissacáridas e conjugadas está a dominar o mercado porque foi relatado que estas vacinas induzem uma forte resposta imunitária em quase todas as pessoas que delas necessitam, incluindo pessoas com o sistema imunitário enfraquecido e problemas de saúde de longo prazo.
- Com base no tipo, o mercado das vacinas está segmentado em vacina de rotina, vacina recomendada e vacina necessária. Em 2021, o segmento das vacinas de rotina está a dominar o mercado porque são utilizadas principalmente para a vacinação infantil e o governo está a colocar grande ênfase na vacinação infantil em todo o mundo.
- Com base na idade de administração, o mercado das vacinas está segmentado em vacinas pediátricas e vacinas para adultos. Em 2021, o segmento das vacinas pediátricas está a dominar o mercado porque as crianças são mais propensas a doenças infeciosas, entre outras, devido ao desenvolvimento do sistema imunitário e, por isso, necessitam de uma vacinação adequada.
- Com base nas doenças, o mercado das vacinas está segmentado em doenças pneumocócicas, sarampo, papeira e varicela, DPT, hepatite, gripe, febre tifóide, meningocócica, raiva, encefalite japonesa, febre amarela e outras. Em 2021, o segmento das doenças pneumocócicas está a dominar o mercado devido ao aumento da prevalência da infeção por pneumonia e ao aumento do lançamento de campanhas de imunização para a melhoria da população.
- On the basis of route of administration, the vaccines market is segmented into injectable, oral and nasal. In 2021, injectable segment is dominating the market because most of the vaccines are administered via parenteral route and induces strong systemic response when injected via same route.
- On the basis of end user, the vaccines market is segmented into community hospitals, hospitals, specialty centres, clinics and others. In 2021, community hospitals segment is dominating the market because most of the vaccination and immunization is carried out by regulatory bodies and concerned authorities.
- On the basis of distribution channel, the vaccines market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy segment is dominating the market because vaccines are directly procured from the company distributors.
Vaccines Market Country Level Analysis
The vaccines market is analyzed and market size information is provided on the basis of composition, type, kind, age of administration, diseases, route of administration, end user and distribution channel as referenced above.
The countries covered in the vaccines market report are the U.S., Canada, and Mexico.
Combination segment in North America region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because vaccines are effective against multiple disease by administration of a single shot. The U.S. is leading the growth of the North America market and combination segment is dominating in this country due to rise in prevalence of government investment for the combination vaccination.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Awareness for Vaccination and Launch of Newer Vaccines are Boosting the Market Growth of Vaccines
Vaccines market also provides you with detailed market analysis for every country growth in Vaccines industry with Vaccines drugs sales, impact of advancement in the Vaccines technology and changes in regulatory scenarios with their support for the Vaccines market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Vaccines Market Share Analysis
O panorama competitivo do mercado de vacinas fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto e respiração, domínio da aplicação, curva da linha de vida da tecnologia. Os dados fornecidos acima estão apenas relacionados com o foco da empresa relacionado com o mercado de vacinas.
As principais empresas que negoceiam vacinas são a Emergent BioSolutions Inc., Dynavax Technologies, Valneva SE, Bavarian Nordic, Altimmune, Merck Sharp & Dohme Corp. , Seqirus (uma subsidiária da CSL Limited), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (uma subsidiária da Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, ALK, Panacea Biotec Ltd, BAXTER VACCINES (uma subsidiária da Baxter), GlaxoSmithKline plc. , Serum Institute of India Unip. entre outros. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos e acordos de produtos são também iniciados por empresas de todo o mundo, que também estão a acelerar o mercado das vacinas.
Por exemplo,
- Em fevereiro de 2020, a Abbott lançou uma nova vacina quadrivalente e de subunidades. A vacina lançada tem a capacidade de fornecer proteção contra quatro estirpes virais da gripe. O produto lançado impulsionou o portefólio de produtos da empresa e permitiu gerar mais receitas.
- Em julho de 2018, a Sanofi lançou a vacina FluQuadri na Índia, que oferece uma melhor proteção contra as quatro estirpes de vacinas contra a gripe. Uma vez que a maioria das vacinas disponíveis contra a gripe são do tipo trivalente, o lançamento deste produto ajudou a empresa a expandir a sua presença no mercado das vacinas e a obter um crescimento rentável no mercado.
A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e reconhecimento, as joint ventures e outras estratégias do player de mercado estão a potenciar o mercado da empresa no mercado das Vacinas, o que também proporciona o benefício para a organização melhorar a sua oferta de vacinas.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA VACCINES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPOSITION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 NORTH AMERICA VACCINES MARKET: LAWS AND REGULATIONS
8 NORTH AMERICA VACCINES MARKET: LOGISTICS OF VACCINES
8.1 COLD CHAIN STORAGE:
8.2 REGULATIONS ASSOCIATED WITH VACCINE SUPPLY
8.3 PROCESS OF LOGISTICS
8.4 CHALLENGES IN LOGISTICS
8.5 CHALLENGES FACED BY INDIA FOR UPCOMING COVID 19 VACCINE:
8.6 CHALLENGES FACED BY LATIN AMERICA FOR UPCOMING VACCINE:
8.7 CHALLENGES FACED BY NIGERIA FOR VACCINE LOGISTICS:
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
9.1.2 HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES
9.1.3 IMPROVEMENT IN TREATMENT
9.1.4 LAUNCH OF NEWER VACCINES
9.1.5 INCREASING GOVERNMENT SUPPORT
9.2 RESTRAINTS
9.2.1 UNAVAILABILITY OF REGISTERED VACCINES
9.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES
9.2.3 DIFFICULTIES ASSOCIATED WITH TRANSPORT AND PRODUCTION OF VACCINES
9.3 OPPORTUNITIES
9.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
9.3.2 PRESENCE OF PIPELINE PRODUCTS
9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
9.3.4 INCREASING AWARENESS FOR VACCINATION
9.4 CHALLENGES
9.4.1 SIDE EFFECTS CAUSED BY VACCINES
9.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
9.4.3 PRODUCT RECALL
10 IMPACT OF COVID-19 ON NORTH AMERICA VACCINES MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON SUPPLY CHAIN
10.3 IMPACT ON DEMAND
10.4 CONCLUSION
11 NORTH AMERICA VACCINES MARKET, BY COMPOSITION
11.1 OVERVIEW
11.2 COMBINATION VACCINES
11.3 MONO VACCINES
12 NORTH AMERICA VACCINES MARKET, BY TYPE
12.1 OVERVIEW
12.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES
12.2.1 PNEUMOCOCCAL DISEASE
12.2.2 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
12.2.3 HPV (HUMAN PAPILLOMA VIRUS)
12.2.4 HEPATITIS B
12.2.5 MENINGOCOCCAL
12.2.6 SHINGLES
12.2.7 WHOOPING COUGH
12.2.8 OTHERS
12.3 LIVE-ATTENUTAED VACCINES
12.3.1 ROTAVIRUS
12.3.2 MEASLES
12.3.3 MUMPS
12.3.4 RUBELLA
12.3.5 SMALLPOX
12.3.6 YELLOW FEVER
12.3.7 OTHERS
12.4 INACTIVATED VACCINES
12.4.1 FLU (SHOT ONLY)
12.4.2 POLIO (SHOT ONLY)
12.4.3 HEPATITIS A
12.4.4 RABIES
12.4.5 OTHERS
12.5 TOXOID VACCINES
12.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP)
12.5.2 OTHERS
12.6 DNA VACCINES
13 NORTH AMERICA VACCINES MARKET, BY KIND
13.1 OVERVIEW
13.2 ROUTINE VACCINE
13.2.1 PNEUMOCOCCAL
13.2.2 DIPHTHERIA
13.2.3 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
13.2.4 MEASLES
13.2.5 MUMPS
13.2.6 HEPATITIS B
13.2.7 RUBELLA
13.2.8 POLIO
13.2.9 OTHERS
13.3 RECOMMENDED VACCINES
13.3.1 TYPHOID FEVER VACCINES
13.3.2 HEPATITIS A
13.3.3 RABIES
13.3.4 JAPANESE ENCEPHALITIS
13.3.5 TICK-BORNE ENCEPHALITIS
13.3.6 CHOLERA
13.3.7 OTHERS
13.4 REQUIRED VACCINES
13.4.1 MENINGOCOCCAL
13.4.2 YELLOW FEVER
13.4.3 OTHERS
14 NORTH AMERICA VACCINES MARKET, BY AGE OF ADMINISTRATION
14.1 OVERVIEW
14.2 PEDIATRIC VACCINES
14.2.1 PNEUMOCOCCAL
14.2.2 MEASLES, MUMPS, AND, RUBELLA
14.2.3 DIPHTHERIA, TETANUS & PERTUSIS (DPT)
14.2.4 ROTAVIRUS
14.2.5 MENINGOCOCCAL
14.2.6 VARICELLA
14.2.7 POLIO
14.2.8 TUBERCULOSIS
14.2.9 MALARIA
14.2.10 OTHERS
14.3 ADULT VACCINES
14.3.1 INLFUENZA
14.3.2 HPV (HUMAN PAPILLOMA VIRUS)
14.3.3 TYPHOID
14.3.4 HEPATITIS B
14.3.5 JAPANESE ENCEPHALITIS
14.3.6 YELLOW FEVER
14.3.7 HIV
14.3.8 CANCER
14.3.9 OTHERS
15 NORTH AMERICA VACCINES MARKET, BY DISEASES
15.1 OVERVIEW
15.2 PNEUMOCCOCAL DISEASE
15.3 MEASLES, MUMPS & RUBELLA
15.4 DPT
15.5 HEPATITIS
15.6 INFLUENZA
15.7 TYPHOID
15.8 MENINGOCOCCAL
15.9 VARICELLA
15.1 RABIES
15.11 JAPANESE ENCEPHALITIS
15.12 YELLOW FEVER
15.13 OTHERS
16 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION
16.1 OVERVIEW
16.2 INJECTABLE
16.2.1 INTRAMUSCULAR
16.2.2 SUBCUTANEOUS
16.2.3 INTRADERMAL
16.3 ORAL
16.4 NASAL
17 NORTH AMERICA VACCINES MARKET, BY END USER
17.1 OVERVIEW
17.2 COMMUNITY HOSPITALS
17.3 HOSPITALS
17.4 SPECIALTY CENTRES
17.5 CLINICS
17.6 OTHERS
18 NORTH AMERICA VACCINES MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
19 NORTH AMERICA VACCINES MARKET, BY GEOGRAPHY
19.1 NORTH AMERICA
19.1.1 U.S.
19.1.2 CANADA
19.1.3 MEXICO
20 NORTH AMERICA VACCINES MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
21 COMPANY PROFILE
21.1 GLAXOSMITHKLINE PLC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.1.6 SWOT ANALYSIS
21.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.2.6 SWOT ANALYS
21.3 SANOFI
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.3.6 SWOT ANALYS
21.4 PFIZER INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.4.6 SWOT ANAL
21.5 ABBOTT
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 ALK
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ALTIMMUNE
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 ASTRAZENECA
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENTS
21.9 BAVARIAN NORDIC
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 BAXTER VACCINES (A SUBSIDIARY OF BAXTER)
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 BHARAT BIOTECH
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 BIO FARMA
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENTS
21.13 BIOLOGICAL E LIMITED
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 DAIICHI SANKYO COMPANY, LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 DYNAVAX TECHNOLOGIES
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 EMERGENT BIOSOLUTIONS INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 F. HOFFMANN-LA ROCHE LTD
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 JANSSEN NORTH AMERICA SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD.,
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PANACEA BIOTEC LTD
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 SEQIRUS (A SUBSIDIARY OF CSL LIMITED)
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
21.21.5 SWOT ANALYSIS
21.22 SERUM INSTITUTE OF INDIA PVT. LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENTS
21.23 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.23.1 COMPANY SNAPSHOT
21.23.2 REVENUE ANALYSIS
21.23.3 PRODUCT PORTFOLIO
21.23.4 RECENT DEVELOPMENTS
21.24 VALNEVA SE
21.24.1 COMPANY SNAPSHOT
21.24.2 REVENUE ANALYSIS
21.24.3 PRODUCT PORTFOLIO
21.24.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 NORTH AMERICA VACCINES MARKET, PIPELINE ANALYSIS
TABLE 2 REGULATIONS IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
TABLE 3 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVEL OF THE COLD CHAIN.
TABLE 4 PROCEDURES FOR REPORTING TO UNICEF VACCINE ARRIVALS.
TABLE 5 LOGISITCS PROCESS ACORSS DIFFERENT REGIONS.
TABLE 6 THE U.S. FUNDING FOR GAVI (2015-2019)
TABLE 7 PRICE OF THE VACCINES BETWEEN THE U.S. AND DEVELOPING COUNTRIES
TABLE 8 VACCINES UNDER CLINICAL TRIAL
TABLE 9 THE SIDE EFFECTS RELATED TO THE VACCINES
TABLE 10 INCREASE IN OPERATIONAL COST COMPONENTS DUE TO COVID-19
TABLE 11 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
TABLE 12 NORTH AMERICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA COMBINATION VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA MONO VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA INACTIVATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA TOXOID VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA ROUTINE VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA RECOMMENDED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA REQUIRED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA PEDIATRIC VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA ADULT VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA PNEUMOCOCCAL DISEASE IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 NORTH AMERICA MEASLES, MUMPS & RUBELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 NORTH AMERICA DPT IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HEPATITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 39 NORTH AMERICA INFLUENZA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 NORTH AMERICA TYPHOID IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 NORTH AMERICA MENINGOCOCCAL IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 42 NORTH AMERICA VARICELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 43 NORTH AMERICA RABIES IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 44 NORTH AMERICA JAPANESE ENCEPHALITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 45 NORTH AMERICA YELLOW FEVER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 46 NORTH AMERICA OTHER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 47 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA INJECTABLE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA ORAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA NASAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA COMMUNITY HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA SPECIALTY CENTRES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA CLINICS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA OTHERS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA HOSPITAL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA RETAIL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA ONLINE PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA VACCINES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 63 NORTH AMERICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 NORTH AMERICA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 77 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 NORTH AMERICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 79 NORTH AMERICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 NORTH AMERICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 U.S. VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 82 U.S. VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 U.S. SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 U.S. LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 U.S. INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 U.S. TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 U.S. VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 88 U.S. ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 89 U.S. RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 90 U.S. REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 91 U.S. VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 92 U.S. PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 93 U.S. ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 94 U.S. VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 95 U.S. VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 U.S. INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 U.S. VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 U.S. VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 CANADA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 100 CANADA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 CANADA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CANADA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 CANADA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 CANADA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 CANADA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 106 CANADA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 107 CANADA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 108 CANADA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 109 CANADA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 CANADA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 111 CANADA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 112 CANADA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 113 CANADA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 114 CANADA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 115 CANADA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 CANADA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 117 MEXICO VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
TABLE 118 MEXICO VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 MEXICO SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 MEXICO LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 MEXICO INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 MEXICO TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 MEXICO VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 124 MEXICO ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 125 MEXICO RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 126 MEXICO REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
TABLE 127 MEXICO VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 128 MEXICO PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 MEXICO ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 130 MEXICO VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
TABLE 131 MEXICO VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 132 MEXICO INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 133 MEXICO VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 134 MEXICO VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 NORTH AMERICA VACCINES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA VACCINES MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA VACCINES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA VACCINES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA VACCINES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA VACCINES MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA VACCINES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA VACCINES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA VACCINES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA VACCINES MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE NORTH AMERICA VACCINES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA VACCINES MARKET IN 2021 & 2028
FIGURE 13 FDA REGULATORY REVIEW PROCESS OF VACCINES
FIGURE 14 AEFI ORGANIZATIONAL STRUCTURES
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA VACCINES MARKET
FIGURE 16 NORTH AMERICA VACCINATION COVERAGE IN THE WORLD (2019)
FIGURE 17 PEDIATRIC DEATHS CAUSED BY INFLUENZA IN THE U.S. (2017 – 2020)
FIGURE 18 NORTH AMERICA PREVALENCE OF HBV INFECTION WORLDWIDE IN 2018
FIGURE 19 HEALTHCARE EXPENDITURE PER CAPITA, 2018
FIGURE 20 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
FIGURE 21 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, 2021
FIGURE 22 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, 2019-2028 (USD MILLION)
FIGURE 23 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, CAGR (2021-2028)
FIGURE 24 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE
FIGURE 25 NORTH AMERICA VACCINES MARKET: BY TYPE, 2021
FIGURE 26 NORTH AMERICA VACCINES MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 27 NORTH AMERICA VACCINES MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 28 NORTH AMERICA VACCINES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 29 NORTH AMERICA VACCINES MARKET: BY KIND, 2019
FIGURE 30 NORTH AMERICA VACCINES MARKET: BY KIND, 2019-2028 (USD MILLION)
FIGURE 31 NORTH AMERICA VACCINES MARKET: BY KIND, CAGR (2021-2028)
FIGURE 32 NORTH AMERICA VACCINES MARKET: BY KIND, LIFELINE CURVE
FIGURE 33 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019
FIGURE 34 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 35 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 36 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 37 NORTH AMERICA VACCINES MARKET: BY DISEASES, 2020
FIGURE 38 NORTH AMERICA VACCINES MARKET: BY DISEASES, 2019-2028 (USD MILLION)
FIGURE 39 NORTH AMERICA VACCINES MARKET: BY DISEASES, CAGR (2021-2028)
FIGURE 40 NORTH AMERICA VACCINES MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 41 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 42 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 43 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 44 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 45 NORTH AMERICA VACCINES MARKET: BY END USER, 2019
FIGURE 46 NORTH AMERICA VACCINES MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 47 NORTH AMERICA VACCINES MARKET: BY END USER, CAGR (2021-2028)
FIGURE 48 NORTH AMERICA VACCINES MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 50 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 51 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 52 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 NORTH AMERICA VACCINES MARKET: SNAPSHOT (2020)
FIGURE 54 NORTH AMERICA VACCINES MARKET: BY COUNTRY (2020)
FIGURE 55 NORTH AMERICA VACCINES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 56 NORTH AMERICA VACCINES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 57 NORTH AMERICA VACCINES MARKET: BY TYPE (2021-2028)
FIGURE 58 NORTH AMERICA VACCINES MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
